The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures \[including secondarily generalized seizures\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).
Participants with epilepsy who received the Fycompa for injection for the first time will be included.
The exclusion criteria will not be specified in particular because this survey will be conducted in daily clinical practice.